Medicine and Dentistry
Systematic Review
64%
Placebo
55%
COVID-19
42%
Drug Effect
42%
Randomized Controlled Trial
38%
Odds Ratio
33%
Randomized Clinical Trial
28%
Blocking Agent
28%
Interleukin 6
28%
Meta-Analysis
26%
Tocilizumab
21%
Sarilumab
15%
Health Care
14%
General Practitioner
14%
Adverse Event
8%
All Cause Mortality
5%
Experimental Drug
5%
Health Expenditure
5%
Nursing and Health Professions
Systematic Review
100%
Clinical Guideline
54%
Confidence Interval
48%
Blocking Agent
28%
Interleukin 6
28%
Advisory Committee
28%
Tocilizumab
26%
Sarilumab
18%
Diseases
16%
Odds Ratio
16%
Placebo
15%
Prevalence
14%
Cross-Sectional Study
14%
Adverse Event
9%
Embase
7%
All Cause Mortality
7%
Peer Review
7%
Journal Impact Factor
7%
Medline
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
69%
Randomized Controlled Trial
28%
Blocking Agent
28%
Interleukin 6
28%
Tocilizumab
21%
Diseases
15%
Randomized Clinical Trial
15%
Sarilumab
15%
Ischemic Heart Disease
14%
Valvular Heart Disease
14%
Population Study
14%
Cross-Sectional Study
14%
Atrial Fibrillation
14%
Long Term Survival
14%
Coronavirinae
14%
Congestive Heart Failure
14%
Adverse Event
8%
All Cause Mortality
5%
